Salk Institute

Technologies Available for Licensing

Selective Modulators of PPAR-gamma and Methods for the Use Thereof

Inventors: Ron Evans and Barry Forman
Potential Uses: Cardiovascular, Obesity, Drug Discovery and Development
Use of PPAR-gamma-selective compounds for the treatment of obesity and diabetes.

Because obesity is associated with the development of serious medical conditions, including noninsulin-dependent diabetes mellitus, hypertension, coronary artery disease, hyperlipidemias and certain malignancies, it is important that compounds to control adiposity are identified. The conversion of fibroblasts into cells of the adipose lineage is induced by expression of the orphan nuclear receptor PPAR-gamma. Accordingly, an endogenous PPAR-gamma ligand may be an important regulator of adipogenesis. This invention reveals PPAR-gamma as a drug target and relates to a class of compounds which are capable of selectively modulating processes mediated by PPAR-gamma. The identification of such compounds makes possible the selective intervention in PPAR-gamma mediated pathways, without exerting inadvertent effects on pathways mediated by other PPAR isoforms.

Salk No: S95031
Patent Status: U.S. Patent No. 6,022,897 issued February 8, 2000
U.S. Patent No. 6,830,882 issued December 14, 2004
Publications: Cell 1995 Dec 1;83(5):803-12
License Terms: Exclusive or Nonexclusive licenses available
Contact: Michelle Booden, Ph.D., Director of Licensing, 858.453.4100 x1612,

Get Involved

Sign up for our email newsletter

Fill out my online form.
Salk Institute for Biological Studies
Street: 10010 N Torrey Pines Rd
City: La Jolla, CA 92037
Phone: 858.453.4100
Charity Navigator Rating
  • Salk Twitter
  • Salk LinkedIn
  • Salk Facebook
  • Salk Instagram
  • Salk Google+
  • Salk YouTube
  • Salk RSS Feed
© Copyright 2015 Salk Institute for Biological Studies | Privacy Policy About Scientists & Research News & Media Events Support